Long-Term Benefit of Empagliflozin on Life Expectancy in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease: Survival Estimates From the EMPA-REG OUTCOME Trial

被引：31
|
作者：
Claggett, Brian [1 ]
Lachin, John M. [2 ]
Hantel, Stefan [3 ]
Fitchett, David [4 ,5 ]
Inzucchi, Silvio E. [6 ]
Woerle, Hans J. [7 ]
George, Jyothis T. [7 ]
Zinman, Bernard [5 ,8 ]
机构：
[1] Brigham & Womens Hosp, Div Cardiovasc Med, 75 Francis St, Boston, MA 02115 USA
[2] George Washington Univ, Biostat Ctr, Rockville, MD USA
[3] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany
[4] St Michaels Hosp, Div Cardiol, Toronto, ON, Canada
[5] Univ Toronto, Toronto, ON, Canada
[6] Yale Univ, Endocrinol Sect, Sch Med, New Haven, CT USA
[7] Boehringer Ingelheim Int GmbH, Ingelheim, Germany
[8] Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON, Canada
来源：
CIRCULATION | 2018年 / 138卷 / 15期
关键词：
cardiovascular diseases; diabetes mellitus; empagliflozin;
D O I：
10.1161/CIRCULATIONAHA.118.033810
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：1599 / 1601
页数：3
相关论文
共 50 条
  • [21] Long-term effects of cilostazol on the prevention of macrovascular disease in patients with type 2 diabetes mellitus
    Rhee, Sang Youl
    Kim, Young Seol
    Chon, Suk
    Oh, Seungjoon
    Woo, Jeong-taek
    Kim, Sung Woon
    Kim, Jin-Woo
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2011, 91 (01) : E11 - E14
  • [22] The effect of EMPAgliflozin on markers of inflammation in patients with concomitant type 2 diabetes mellitus and Coronary ARtery Disease: the EMPA-CARD randomized controlled trial
    Gohari, Sepehr
    Reshadmanesh, Tara
    Khodabandehloo, Hadi
    Karbalaee-Hasani, Amir
    Ahangar, Hassan
    Arsang-Jang, Shahram
    Ismail-Beigi, Faramarz
    Dadashi, Mohsen
    Ghanbari, Samin
    Taheri, Homa
    Fathi, Mojtaba
    Muhammadi, Muhammad Javad
    Mahmoodian, Reyhaneh
    Asgari, Atieh
    Tayaranian, Mohammadreza
    Moharrami, Mehdi
    Mahjani, Mahsa
    Ghobadian, Bijan
    Chiti, Hossein
    Gohari, Sheida
    DIABETOLOGY & METABOLIC SYNDROME, 2022, 14 (01)
  • [23] The effect of EMPAgliflozin on markers of inflammation in patients with concomitant type 2 diabetes mellitus and Coronary ARtery Disease: the EMPA-CARD randomized controlled trial
    Sepehr Gohari
    Tara Reshadmanesh
    Hadi Khodabandehloo
    Amir Karbalaee-Hasani
    Hassan Ahangar
    Shahram Arsang-Jang
    Faramarz Ismail-Beigi
    Mohsen Dadashi
    Samin Ghanbari
    Homa Taheri
    Mojtaba Fathi
    Muhammad Javad Muhammadi
    Reyhaneh Mahmoodian
    Atieh Asgari
    Mohammadreza Tayaranian
    Mehdi Moharrami
    Mahsa Mahjani
    Bijan Ghobadian
    Hossein Chiti
    Sheida Gohari
    Diabetology & Metabolic Syndrome, 14
  • [24] Coronary Artery Calcium Score as a Sensitive Indicator of Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus: A Long-Term Cohort Study
    Koo, Dae-Jeong
    Lee, Mi Yeon
    Moon, Sun Joon
    Kwon, Hyemi
    Lee, Sang Min
    Park, Se Eun
    Park, Cheol-Young
    Lee, Won-Young
    Oh, Ki Won
    Cho, Sung Rae
    Jeong, Young-Hoon
    Rhee, Eun-Jung
    ENDOCRINOLOGY AND METABOLISM, 2023, 38 (05) : 568 - 577
  • [25] Long-term treatment with empagliflozin as add-on to oral antidiabetes therapy in Japanese patients with type 2 diabetes mellitus
    Araki, E.
    Tanizawa, Y.
    Tanaka, Y.
    Taniguchi, A.
    Koiwai, K.
    Kim, G.
    Salsali, A.
    Woerle, H. J.
    Broedl, U. C.
    DIABETES OBESITY & METABOLISM, 2015, 17 (07) : 665 - 674
  • [26] Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease Results of the VERTIS CV Trial
    Cosentino, Francesco
    Cannon, Christopher P.
    Cherney, David Z. I.
    Masiukiewicz, Urszula
    Pratley, Richard
    Dagogo-Jack, Sam
    Frederich, Robert
    Charbonnel, Bernard
    Mancuso, James
    Shih, Weichung J.
    Terra, Steven G.
    Cater, Nilo B.
    Gantz, Ira
    McGuire, Darren K.
    CIRCULATION, 2020, 142 (23) : 2205 - 2215
  • [27] Study rationale and design of a study of EMPAgliflozin’s effects in patients with type 2 diabetes mellitus and Coronary ARtery disease: the EMPA-CARD randomized controlled trial
    Sepehr Gohari
    Tara Reshadmanesh
    Hadi Khodabandehloo
    Mojtaba Fathi
    Hassan Ahangar
    Shahram Arsang-Jang
    Faramarz Ismail-Beigi
    Samin Ghanbari
    Mohsen Dadashi
    Muhammad Javad Muhammadi
    Sheida Gohari
    Saeid Ghaffari
    BMC Cardiovascular Disorders, 21
  • [28] Empagliflozin and left atrial function in patients with type 2 diabetes mellitus and coronary artery disease: insight from the EMPA-HEART CardioLink-6 randomized clinical trial
    Pourafkari, Marina
    Connelly, Kim A.
    Verma, Subodh
    Mazer, C. David
    Teoh, Hwee
    Quan, Adrian
    Goodman, Shaun G.
    Rai, Archana
    Ng, Ming Yen
    Deva, Djeven P.
    Triverio, Piero
    Jiminez-Juan, Laura
    Yan, Andrew T.
    Ge, Yin
    CARDIOVASCULAR DIABETOLOGY, 2024, 23 (01)
  • [29] Study rationale and design of a study of EMPAgliflozin's effects in patients with type 2 diabetes mellitus and Coronary ARtery disease: the EMPA-CARD randomized controlled trial
    Gohari, Sepehr
    Reshadmanesh, Tara
    Khodabandehloo, Hadi
    Fathi, Mojtaba
    Ahangar, Hassan
    Arsang-Jang, Shahram
    Ismail-Beigi, Faramarz
    Ghanbari, Samin
    Dadashi, Mohsen
    Muhammadi, Muhammad Javad
    Gohari, Sheida
    Ghaffari, Saeid
    BMC CARDIOVASCULAR DISORDERS, 2021, 21 (01)
  • [30] Secondary Prevention of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus International Insights From the TECOS Trial (Trial Evaluating Cardiovascular Outcomes With Sitagliptin)
    Pagidipati, Neha J.
    Navar, Ann Marie
    Pieper, Karen S.
    Green, Jennifer B.
    Bethel, M. Angelyn
    Armstrong, Paul W.
    Josse, Robert G.
    McGuire, Darren K.
    Lokhnygina, Yuliya
    Cornel, Jan H.
    Halvorsen, Sigrun
    Strandberg, Timo E.
    Delibasi, Tuncay
    Holman, Rury R.
    Peterson, Eric D.
    CIRCULATION, 2017, 136 (13) : 1193 - +
12345